Hoe verhoudt UCB N's PE Ratio zich tot zijn concurrenten?

UCB N is duur op basis van de Price-To-Earnings -ratio ( 38.1 x) vergeleken met het gemiddelde van de peer ( 35.6 x).

Hoe verhoudt UCB N's PE Ratio zich tot andere bedrijven in de Global Pharmaceuticals industrie?

UCB N is duur op basis van de Price-To-Earnings -ratio ( 38.1 x) vergeleken met het South American Pharmaceuticals -industriegemiddelde ( 8.7 x).

Wat is UCB N's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Earnings Fair Ratio van { UCB N te berekenen voor waarderinganalyse.

Wat is de reële prijs van UCB N als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

UCB N ( MX$1692.27 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( MX$2219.57 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

UCB (BMV:UCB N) - Aandelenkoers, Nieuws & Analyse

UCB N Overzicht aandelen

A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. Meer informatie

UCB N fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	3/6
Prestaties in het verleden	2/6
Financiële gezondheid	4/6
Dividenden	4/6

Beloningen

Verhandeld tegen 23.8% onder onze schatting van de reële waarde

De winst zal naar verwachting met 23.85% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Winstmarges (7.7%) zijn lager dan vorig jaar (18.3%)

UCB SA Concurrenten

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.9b

Astellas Pharma

TSE:4503

JP¥2.8t

Hansoh Pharmaceutical Group

SEHK:3692

HK$110.6b

Yunnan Baiyao GroupLtd

SZSE:000538

CN¥100.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor UCB
Historische aandelenkoersen
Huidige aandelenkoers	€1,692.27
52 Week Hoogtepunt	€1,861.24
52 Week Laag	€1,692.27
Bèta	0.33
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	-28.40%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-21.67%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	UCB N	MX Pharmaceuticals	MX Markt
7D	0%	-2.5%	-1.0%
1Y	-28.4%	-17.5%	-3.3%

Rendement versus industrie: UCB N presteerde slechter dan de MX Pharmaceuticals -sector, die het afgelopen jaar een rendement van -17.5 % opleverde.

Rendement versus markt: UCB N presteerde slechter dan MX Market, dat het afgelopen jaar een rendement van -3.3 % opleverde.

Prijsvolatiliteit

Is UCB N's price volatile compared to industry and market?
UCB N volatility
UCB N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.1%
10% least volatile stocks in MX Market	2.6%

Stabiele aandelenkoers: UCB N heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van UCB N in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1925	8,406	Jean-Christophe Tellier	www.ucb.com

UCB SA Samenvatting

Hoe verhouden de winst en inkomsten van UCB zich tot de beurswaarde?
UCB N fundamentele statistieken
Marktkapitalisatie	Mex$322.25b
Inkomsten(TTM)	Mex$8.35b
Inkomsten(TTM)	Mex$108.23b

38.1x

Koers/Winstverhouding

2.9x

P/S-verhouding

Is UCB N overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
UCB N resultatenrekening (TTM)
Inkomsten	€5.45b
Kosten van inkomsten	€1.67b
Brutowinst	€3.77b
Overige uitgaven	€3.35b
Inkomsten	€420.00m

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	2.22
Brutomarge	69.27%
Nettowinstmarge	7.71%
Schuld/Eigen Vermogen Verhouding	30.5%

Hoe presteerde UCB N op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.6%

Huidig dividendrendement

60%

Uitbetalingsratio

Betaalt UCB N een betrouwbaar dividend?

Zie UCB N dividendgeschiedenis en benchmarks

Wanneer moet je UCB N kopen om een aanstaand dividend te ontvangen?
UCB dividenddata
Ex Dividend Datum	Apr 28 2023
Betaaldatum dividend	May 03 2023
Dagen tot Ex-dividend	579 days
Dagen tot dividendbetaaldatum	574 days

Betaalt UCB N een betrouwbaar dividend?

Zie UCB N dividendgeschiedenis en benchmarks

UCB N Overzicht aandelen

Beloningen

Risicoanalyse

UCB SA Concurrenten

BMV:LAB B

Mex$24.9b

TSE:4503

JP¥2.8t

SEHK:3692

HK$110.6b

SZSE:000538

CN¥100.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

Investor sentiment deteriorated over the past week

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

Upcoming dividend of €0.91 per share

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020)

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Independent Vice Chairman Pierre Gurdjian has left the company

Chairman Diégo du de Bergendal has left the company

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

Full year 2020 earnings released: EPS €3.87 (vs €4.22 in FY 2019)

Revenue beats expectations